Clinical Report: Effectiveness of Tumor Treating Fields in High-Grade Gliomas
Overview
This retrospective study evaluates the efficacy of Tumor Treating Fields (TTFields) in 28 patients with high-grade gliomas. The findings indicate that TTFields therapy is well tolerated, with high treatment adherence.
Background
High-grade gliomas, particularly glioblastoma, represent a significant challenge in neuro-oncology due to their aggressive nature and poor prognosis. Current treatment strategies often yield limited survival benefits.
Data Highlights
Patient Cohort
Median PFS (months)
Median OS (months)
Newly Diagnosed
18.1
22.0
Recurrent
9.1
18.2
Key Findings
Median duration of TTFields use was 9.4 months with an adherence rate of 88.05%.
Newly diagnosed patients had a median progression-free survival (PFS) of 18.1 months and overall survival (OS) of 22.0 months.
Recurrent patients exhibited a median PFS of 9.1 months and OS of 18.2 months.
Common adverse events included grade 1–2 dermatologic reactions, with no grade 3–4 toxicities reported.
Findings are consistent with previously reported clinical and real-world data, though caution is advised due to the small sample size.
Clinical Implications
Clinicians should be aware of the adherence and tolerability of TTFields in the management of gliomas.
Conclusion
The findings from this retrospective analysis indicate that TTFields therapy is a well-tolerated treatment option for high-grade gliomas.
